Adnan Deronic (Former)
1 – 10 of 12
      - show: 10
- |
- sort: year (new to old)
        Close
        
            
    
    Embed this list
<iframe src=""
              width=""
              height=""
              allowtransparency="true"
              frameborder="0">
            </iframe>
        - 2023
- 
                        Mark
        The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
    
    - Contribution to journal › Article
 
- 2022
- 
                        Mark
        Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
    
    - Contribution to journal › Article
 
- 2021
- 
                        Mark
        Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy
    
    - Contribution to journal › Scientific review
 
- 
                        Mark
        The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo
    
    - Contribution to journal › Article
 
- 2019
- 
                        Mark
        First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies
    
    - Contribution to journal › Article
 
- 2018
- 
                        Mark
        The immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis
    
    - Contribution to journal › Article
 
- 2016
- 
                        Mark
        The anti-tumor effect of the quinoline-3-carboxamide tasquinimod : Blockade of recruitment of CD11b+ Ly6Chi cells to tumor tissue reduces tumor growth
    
    - Contribution to journal › Article
 
- 2015
- 
                        Mark
        A1M/α1-microglobulin is proteolytically activated by myeloperoxidase, binds its heme group and inhibits low density lipoprotein oxidation.
    
    - Contribution to journal › Article
 
- 
                        Mark
        Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment.
    
    - Contribution to journal › Article
 
- 
                        Mark
        Effect of quinoline-3-carboxamides on myeloid cells in inflammation and cancer
    
    - Thesis › Doctoral thesis (compilation)
 
